Conference Presentation, Panel
London Summit 2015 - Tech Rx: Harnessing Big Data to Cure Disease
Milken InstituteMargaret Anderson, Mary Baker, Albert Bourla, Gianrico Farrugia, Nicole Mather, Nicola Perrin
- Precision medicine is transitioning from narrative to practical benefit, with forecasts indicating breathtaking progress in treatments, cures, and interventions within one year.
- Financial sustainability concerns in Europe are intensifying regarding brain disease spending, which totaled 800 billion euros annually as of 2014.
- Demographic shifts are projected to see two-thirds of the global population surviving to age 65, driving a strategic pivot toward prevention and the mitigation of deterioration.
- Mobile applications are predicted to surpass healthcare professionals in impacting patient health, with younger generations expected to adopt these tools as the primary mode of health communication.
- Consumer behavior is shifting toward self-management and wellness-focused technologies, where individuals seek ownership of their disease and control over information access limits.
- Regulatory bodies, including the FDA, are expected to evolve to accommodate new data frameworks for drug approval and outcome measurement.
- The collection of extensive data will necessitate a paradigm shift in information governance, requiring new safeguards and trust mechanisms to maximize data utility.
- Big data is forecast to permeate all health sectors, including drug development, administration, and daily healthy living practices.
- Ethical challenges regarding family access to elderly relatives' data and transatlantic data transfer obstacles, such as the European Court decision, require resolution.
- Long-term goals aim to widely distribute prevention opportunities and medical interventions globally, extending far beyond the current continent or group.